Dr. Maria Debiec-Rychter

Home/Tag: Dr. Maria Debiec-Rychter

Potential Treatment for Imatinib-Resistant GIST Explored

Dr. Ron DeMatteo GIST specialist surgeon Dr. Ron DeMatteo, along with colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC), has published a new paper in the April issue of Cancer Research with potentially [...]

By |2019-10-31T12:01:35-04:00June 16th, 2015|Drug Treatment, News, Research|

Strategies to rapidly identify and validate new therapies for GIST

By Dr. Anette Duensing, University of Pittsburgh Cancer Institute, and Dr. Maria Debiec-Rychter, KU Leuven, Belgium, LRG Research Team Dr. Maria Debiec-Rychter Dr. Anette Duensing Although most GISTs initially respond well [...]

By |2019-09-20T12:36:26-04:00October 24th, 2014|Drug Treatment, News, Research|

2013 LRG Research Team Progress Report

Accomplishments—Recent Progress: 1. Using mouse models, successfully attacked GIST with antibodies, essentially telling immune system to eat the cancer cells.

The Life Raft Group Attends 18th Annual CTOS Meeting in NYC

From October 30th to November 2nd the Life Raft Group staff members attended the annual Connective Tissue Oncology Society (CTOS) Meeting in NYC.

By |2019-09-20T11:36:08-04:00December 6th, 2013|Advocacy, Clinical Trials, Drug Treatment, News, Research|

LRG researchers publish study on DREAM complex – an important regulator of GIST “cell sleep”

A study about the DREAM complex was published in the June issue of Cancer Research by LRG Research Team members Drs. Anette Duensing and Maria Debiec-Rychter.

By |2019-09-20T12:24:44-04:00July 5th, 2013|News, Research|

LRG & colleagues make their mark on 17th annual CTOS meeting in Prague

Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.

By |2019-09-20T13:18:16-04:00February 1st, 2013|Events, News|

LRG Research Team members publish results of imatinib combination study

Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).

By |2019-09-20T13:20:42-04:00February 1st, 2013|News, Research|
Go to Top